Cargando…
Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resista...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234648/ https://www.ncbi.nlm.nih.gov/pubmed/35238496 http://dx.doi.org/10.1002/hep4.1928 |
_version_ | 1784736126845583360 |
---|---|
author | Hou, Wei Bridgeman, Bryan Malnassy, Greg Ding, Xianzhong Cotler, Scott J. Dhanarajan, Asha Qiu, Wei |
author_facet | Hou, Wei Bridgeman, Bryan Malnassy, Greg Ding, Xianzhong Cotler, Scott J. Dhanarajan, Asha Qiu, Wei |
author_sort | Hou, Wei |
collection | PubMed |
description | Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC. The elevated expression of ITGB8 was observed in LR HCC cells. Furthermore, silencing of ITGB8 reversed lenvatinib resistance in vitro and in vivo, whereas ectopic expression of ITGB8 in lenvatinib‐sensitive parental HCC cells exhibited increased resistance to lenvatinib. Mechanistically, ITGB8 regulated lenvatinib resistance through an HSP90‐mediated stabilization of AKT and enhanced AKT signaling. In support of this model, either an AKT inhibitor MK‐2206 or an HSP90 inhibitor 17‐AAG resensitized LR HCC cells to lenvatinib treatment. Conclusion: Collectively, our results establish a crucial role of ITGB8 in lenvatinib resistance, and suggest that targeting the ITGB8/HSP90/AKT axis is a promising therapeutic strategy in patients with HCC exhibiting lenvatinib resistance. |
format | Online Article Text |
id | pubmed-9234648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92346482022-06-30 Integrin subunit beta 8 contributes to lenvatinib resistance in HCC Hou, Wei Bridgeman, Bryan Malnassy, Greg Ding, Xianzhong Cotler, Scott J. Dhanarajan, Asha Qiu, Wei Hepatol Commun Original Articles Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC. The elevated expression of ITGB8 was observed in LR HCC cells. Furthermore, silencing of ITGB8 reversed lenvatinib resistance in vitro and in vivo, whereas ectopic expression of ITGB8 in lenvatinib‐sensitive parental HCC cells exhibited increased resistance to lenvatinib. Mechanistically, ITGB8 regulated lenvatinib resistance through an HSP90‐mediated stabilization of AKT and enhanced AKT signaling. In support of this model, either an AKT inhibitor MK‐2206 or an HSP90 inhibitor 17‐AAG resensitized LR HCC cells to lenvatinib treatment. Conclusion: Collectively, our results establish a crucial role of ITGB8 in lenvatinib resistance, and suggest that targeting the ITGB8/HSP90/AKT axis is a promising therapeutic strategy in patients with HCC exhibiting lenvatinib resistance. John Wiley and Sons Inc. 2022-03-03 /pmc/articles/PMC9234648/ /pubmed/35238496 http://dx.doi.org/10.1002/hep4.1928 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hou, Wei Bridgeman, Bryan Malnassy, Greg Ding, Xianzhong Cotler, Scott J. Dhanarajan, Asha Qiu, Wei Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title | Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title_full | Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title_fullStr | Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title_full_unstemmed | Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title_short | Integrin subunit beta 8 contributes to lenvatinib resistance in HCC |
title_sort | integrin subunit beta 8 contributes to lenvatinib resistance in hcc |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234648/ https://www.ncbi.nlm.nih.gov/pubmed/35238496 http://dx.doi.org/10.1002/hep4.1928 |
work_keys_str_mv | AT houwei integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT bridgemanbryan integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT malnassygreg integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT dingxianzhong integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT cotlerscottj integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT dhanarajanasha integrinsubunitbeta8contributestolenvatinibresistanceinhcc AT qiuwei integrinsubunitbeta8contributestolenvatinibresistanceinhcc |